Friday, November 12, 2021 8:58:47 AM
Relief Therapeutics and AdVita Lifescience are set to enrol the first patient in a Phase II trial of an inhaled formulation of the former’s lead compound, RLF-100 (aviptadil), for preventing Covid-19-related acute respiratory distress syndrome (ARDS).
Relief Therapeutics and AdVita Lifescience are set to enrol the first patient in a Phase II trial of an inhaled formulation of the former’s lead compound, RLF-100 (aviptadil), for preventing Covid-19-related acute respiratory distress syndrome (ARDS).
A synthetic form of a vasoactive intestinal peptide, aviptadil is being developed by NeuroRx as Zyesami in partnership with Relief Therapeutics.
Named ‘Inhaled Aviptadil for the Prevention of COVID-19 Related ARDS’, the randomised, double-blind, placebo-controlled trial will be carried out at various clinical sites in Switzerland.
https://www.clinicaltrialsarena.com/news/relief-advita-ards-prevention/
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM